Search Results for "mesalamine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for mesalamine. Results 1 to 10 of 10 total matches.
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
budesonide Rayos prednisone Rowasa mesalamine Azulfidine Entyvio sulfasalazine olsalazine Inflectra ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
)
flAntacids, PPIs, and H2RAs may alter release of ER and DR mesalamine formulations
flSulfasalazine ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
of
multiple sclerosis.1
STANDARD TREATMENT — An aminosalicylate such
as mesalamine (Lialda, and others ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Table 1).4 In distal UC and proctitis,
mesalamine suppositories or enemas may be more
effective than ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
phthalate, a plasticizer in the enteric coating; currently available mesalamine formulations
do not contain ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
in the US for this indication; ozanimod (Zeposia) was the first.1
STANDARD TREATMENT — An aminosalicylate such as mesalamine ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
disease.
STANDARD TREATMENT — An aminosalicylate such
as mesalamine (Lialda, and others) is generally ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
and
psoriatic arthritis.1
STANDARD TREATMENT — An aminosalicylate such
as mesalamine (Lialda, and others ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4 doi:10.58347/tml.2024.1715d | Show Introduction Hide Introduction
Guselkumab (Tremfya) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
earlier.1,2
STANDARD TREATMENT — An aminosalicylate such
as mesalamine (Lialda, and others) is generally ...
The interleukin (IL)-23 antagonist guselkumab
(Tremfya – Janssen Biotech) has now been approved
by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was
approved earlier for treatment of plaque psoriasis
and psoriatic arthritis. Guselkumab is the third IL-23
antagonist to be approved in the US for treatment of
UC; risankizumab (Skyrizi) and mirikizumab (Omvoh)
were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8 doi:10.58347/tml.2025.1724d | Show Introduction Hide Introduction
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
— An aminosalicylate such
as mesalamine (Lialda, and others) is used as firstline
treatment for both induction ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.